Title
Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium : a sub-analysis of the PROPHESYS study Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in Belgium : a sub-analysis of the PROPHESYS study
Author
Contributor
Michielsen, P.
Author
Faculty/Department
Faculty of Medicine and Health Sciences
Publication type
article
Publication
Bruxelles ,
Subject
Human medicine
Source (journal)
Acta gastro-enterologica belgica. - Bruxelles, 1996 - 2007
Volume/pages
77(2014) :1 , p. 30-40
ISSN
1784-3227
ISI
000341234500006
Carrier
E
Target language
English (eng)
Affiliation
University of Antwerp
Abstract
Background and study aims : PROPHESYS was a prospective, international cohort study of monoinfected, treatment-naive chronic hepatitis C patients treated with a combination of peginterferon alfa-2a or alfa-2b and ribavirin. It included worldwide 7,163 patients from 19 countries (including 384 patients from Belgium alone) and demonstrated that sustained virologic response rates in the real world were similar to those achieved in well-controlled clinical trials. The objective of this sub-analysis was to present an overview of the baseline characteristics, anti-hepatitis C drug treatment, and virologic responses of the patients treated in Belgium, infected with HCV genotype 1, 2, 3, or 4, and administered peginterferon alfa-2a. Moreover, the impact of ribavirin dosage on the response to treatment was studied. Patients and methods : 356 patients were included in this subanalysis. All variables were summarized using descriptive statistics. Results : Compared to the published data of the whole study population (1), the Belgian data presented some significant differences in terms of genotype distribution and response to treatment (e.g. lower prevalence of HCV genotype 1 infection, lower virologic response rates in HCV genotype 2 patients). Deviations from existing recommendations were identified (e.g. higher dose of ribavirin in HCV genotype 2 or 3 patients). Patients who received less than 80% of the target dose of ribavirin experienced a significantly weaker response to treatment. Conclusion : This sub-analysis provided an interesting profile of the Belgian experience in the treatment of chronic hepatitis C.
E-info
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341234500006&DestLinkType=RelatedRecords&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000341234500006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=ef845e08c439e550330acc77c7d2d848
Handle